CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
MT-1186drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04176224
NCT04176224Phase 1Completed
CompareCT.gov

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

Tanabe Pharma Corporation·interventional·Posted Nov 25, 2019·Updated May 22, 2026

In Brief

A Phase 1 clinical trial evaluating MT-1186 for Japanese Patients With ALS. Completed, enrolled 9 participants across 1 site.

Detailed Summary

To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Patients with Amyotrophic Lateral Sclerosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Patients With ALS
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 25, 2019
Enrollment StartApr 17, 2019
Primary CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.6 years ago

Interventions

MT-1186drug

Suspension